Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 Season

Takeyuki Goto(Fukuoka City Hospital), Hideyuki Ikematsu, Yoshio Takasaki, Naoki Kawai(Japan Medical Association), Naoki Tani(University of Tsukuba), Takuma Bando(Japan Medical Association), Yong Chong, Shizuo Shindo, Tomonori Sato(Tohoku University)

Influenza and Other Respiratory Viruses

November 1, 2024

10.1111/irv.70042

Cited by 5

Related Papers

Submucosal tumors: Comprehensive guide for the diagnosis and therapy of gastrointestinal submucosal tumors

|Digestive Endoscopy|2013|278

Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group

|Gut|2012|258

Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy

|European Heart Journal|2019|235

Clinical outcomes of endoscopic submucosal dissection for superficial esophageal neoplasms: a multicenter retrospective cohort study

|Endoscopy|2015|206

A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003-2004 and 2004-2005 Influenza Seasons

|Clinical Infectious Diseases|2006|193